Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors
Authors
Keywords
-
Journal
Arthritis & Rheumatology
Volume 69, Issue 2, Pages 277-290
Publisher
Wiley
Online
2016-11-18
DOI
10.1002/art.39944
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges
- (2015) Josef S. Smolen et al. Nature Reviews Rheumatology
- Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study
- (2015) Mark C. Genovese et al. Arthritis & Rheumatology
- 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
- (2015) Jasvinder A. Singh et al. Arthritis & Rheumatology
- How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?
- (2014) Roy Fleischmann et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study
- (2014) Mark C Genovese et al. ANNALS OF THE RHEUMATIC DISEASES
- Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy
- (2014) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Interleukin 6 and Rheumatoid Arthritis
- (2014) Yuji Yoshida et al. Biomed Research International
- The Biology and Medical Implications of Interleukin-6
- (2014) T. Tanaka et al. Cancer Immunology Research
- Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial
- (2013) Tom W J Huizinga et al. ANNALS OF THE RHEUMATIC DISEASES
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
- (2013) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
- (2013) Gerd R Burmester et al. LANCET
- Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement
- (2012) Monika M Schoels et al. ANNALS OF THE RHEUMATIC DISEASES
- Multiple Courses of Rituximab Produce Sustained Clinical and Radiographic Efficacy and Safety in Patients with Rheumatoid Arthritis and an Inadequate Response to 1 or More Tumor Necrosis Factor Inhibitors: 5-Year Data from the REFLEX Study
- (2012) E. C. KEYSTONE et al. JOURNAL OF RHEUMATOLOGY
- Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment
- (2012) P. Emery RHEUMATOLOGY
- Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction
- (2011) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative
- (2010) Daniel Aletaha et al. ARTHRITIS AND RHEUMATISM
- Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu
- (2010) Joel M. Kremer et al. ARTHRITIS AND RHEUMATISM
- Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials
- (2010) L. Campbell et al. RHEUMATOLOGY
- The role of Interleukin 6 in the pathophysiology of rheumatoid arthritis
- (2010) Srinivasan Srirangan et al. Therapeutic Advances in Musculoskeletal Disease
- Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide
- (2009) J R Curtis et al. ANNALS OF THE RHEUMATIC DISEASES
- Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
- (2009) G. Jones et al. ANNALS OF THE RHEUMATIC DISEASES
- Total cholesterol and LDL levels decrease before rheumatoid arthritis
- (2009) E. Myasoedova et al. ANNALS OF THE RHEUMATIC DISEASES
- Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo
- (2009) Roland Axmann et al. ARTHRITIS AND RHEUMATISM
- IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
- (2008) P. Emery et al. ANNALS OF THE RHEUMATIC DISEASES
- Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study
- (2008) Mark C. Genovese et al. ARTHRITIS AND RHEUMATISM
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More